Glucose‐Oxidase Conjugated Cerium Oxide‐Based Super Nanozyme for Rapid MRSA Eradication and Wound Closure
Source abstract
Abstract
ABSTRACT The global rise of antibiotic‐resistant pathogens poses a serious challenge to public health, particularly in the healing of infected chronic wounds. Innovative, safe, and therapeutically adaptive strategies are urgently required to combat antimicrobial resistance (AMR) pathogens. A glucose‐oxidase conjugated cerium oxide nanoparticle (CeO 2 NPs‐GOx)‐based nanozyme displaying oxidase‐mimetic activity at physiological pH and wound exudate is developed. The conjugate displays potent antibacterial activity and eradication of β‐lactamase‐producing clinical isolates of methicillin‐resistant Staphylococcus aureus (MRSA) by producing superoxide and hydroxyl radicals in the presence of adenosine triphosphate (ATP) and glucose. Microscopic imaging, lactate dehydrogenase (LDH) release and lipid peroxidation assays revealed compromised bacterial cell wall structure and release of cytoplasmic contents due to the continuous production of free radicals. The in vivo MRSA‐infected wound data showed that application of CeO 2 NPs‐GOx led to infection clearance within a week, as well as better wound closure than vancomycin. Upon CeO 2 NPs‐GOx treatment, wound tissues undergo enhanced re‐epithelialization, collagen deposition, and angiogenesis, while reduced production of pro‐inflammatory cytokines (IL‐6, TNF‐α, and IL‐1β). CeO 2 NPs‐GOx exposure displayed almost no accumulation rather rapid clearance of nanozymes from the body. Overall, this study establishes CeO 2 NPs‐GOx as an effective antibacterial nanozyme, integrating ATP‐assisted oxidase‐mimetic activity, exhibiting reactive oxygen species (ROS)‐mediated elimination of MRSA infection from wounds. Thus, the developed novel CeO 2 NPs‐based nanozyme offers an alternative to antibiotics for clinical translation and effective control of AMR spread.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Nanobiology and Nanozymology Research Laboratory BRIC‐National Institute of Animal Biotechnology (NIAB) Hyderabad Telangana India
DBT‐Regional Centre for Biotechnology (RCB) Faridabad Haryana India
Funding
Department of Biotechnology, Government of West Bengal
References (87)
Show source-provided references
1. Siddiqui A. H. · 2025
2. 10.1038/s41551-017-0187-510.1038/s41551-017-0187-5 ↗
3. 10.1016/j.addr.2017.09.01510.1016/j.addr.2017.09.015 ↗
4. 10.2174/13816120677902624510.2174/138161206779026245 ↗
5. 10.1002/jps.260084072110.1002/jps.2600840721 ↗
6. 10.1016/j.jconrel.2009.11.01210.1016/j.jconrel.2009.11.012 ↗
7. 10.1016/j.bmc.2009.02.04310.1016/j.bmc.2009.02.043 ↗
8. 10.2147/NSA.S13341510.2147/NSA.S133415 ↗
9. 10.3390/pharmaceutics1412259910.3390/pharmaceutics14122599 ↗
10. 10.3109/13880209.2014.89300110.3109/13880209.2014.893001 ↗
11. 10.1016/j.inoche.2020.10828110.1016/j.inoche.2020.108281 ↗
12. Antibacterial Activity of Nanoparticles of Titanium Dioxide, Intrinsic and Doped with Indium and Iron
13. 10.1088/1402-4896/ade29b10.1088/1402-4896/ade29b ↗
14. 10.1016/j.mseb.2025.11872110.1016/j.mseb.2025.118721 ↗
15. 10.1016/j.ijbiomac.2024.13511810.1016/j.ijbiomac.2024.135118 ↗
16. 10.3390/ijms23211365510.3390/ijms232113655 ↗
17. 10.1016/j.procbio.2020.05.00310.1016/j.procbio.2020.05.003 ↗
18. 10.1021/acsami.0c1098110.1021/acsami.0c10981 ↗
19. 10.1186/s12951-019-0487-x10.1186/s12951-019-0487-x ↗
20. Intrinsic Oxidase‐Like Nanoenzyme Co4S3/Co(OH)2 Hybrid Nanotubes with Broad‐Spectrum Antibacterial Activity
21. 10.1159/00036763210.1159/000367632 ↗
22. 10.1371/journal.pone.015444510.1371/journal.pone.0154445 ↗
23. 10.1155/2019/541696310.1155/2019/5416963 ↗
24. 10.1016/j.jcis.2023.10.05010.1016/j.jcis.2023.10.050 ↗
25. 10.1016/j.jcis.2015.06.01510.1016/j.jcis.2015.06.015 ↗
26. 10.1016/j.colsurfb.2017.02.00410.1016/j.colsurfb.2017.02.004 ↗
27. 10.1016/j.colsurfb.2023.11353110.1016/j.colsurfb.2023.113531 ↗
28. 10.3390/biom1203047210.3390/biom12030472 ↗
29. 10.1007/s00253-008-1407-410.1007/s00253-008-1407-4 ↗
30. 10.26599/NR.2025.9490701210.26599/NR.2025.94907012 ↗
31. 10.1016/j.mtbio.2025.10240510.1016/j.mtbio.2025.102405 ↗
32. 10.1021/acsami.9b0300410.1021/acsami.9b03004 ↗
33. 10.1002/adfm.20191008510.1002/adfm.201910085 ↗
34. 10.1002/adma.20241777410.1002/adma.202417774 ↗
35. 10.2174/011381612830266724042211022610.2174/0113816128302667240422110226 ↗
36. 10.1007/s00011-019-01220-410.1007/s00011-019-01220-4 ↗
37. 10.1016/j.talanta.2023.12505210.1016/j.talanta.2023.125052 ↗
38. Particle Size Effect on the Properties of Cerium Oxide (CeO2) Nanoparticles Synthesized by Hydrothermal Method
39. 10.1021/acsanm.0c0296010.1021/acsanm.0c02960 ↗
40. 10.1016/j.colsurfb.2026.11560610.1016/j.colsurfb.2026.115606 ↗
41. 10.1177/204173141771839110.1177/2041731417718391 ↗
42. 10.3390/nano702003910.3390/nano7020039 ↗
43. 10.1039/D5NR00430F10.1039/D5NR00430F ↗
44. 10.1063/1.206187310.1063/1.2061873 ↗
45. 10.1016/j.ijbiomac.2024.13670010.1016/j.ijbiomac.2024.136700 ↗
46. 10.1016/j.jallcom.2009.12.05310.1016/j.jallcom.2009.12.053 ↗
47. 10.1186/1556-276X-9-14210.1186/1556-276X-9-142 ↗
48. 10.1039/C7RA02592K10.1039/C7RA02592K ↗
49. 10.1093/nar/gks58110.1093/nar/gks581 ↗
50. 10.1007/s00449-015-1408-510.1007/s00449-015-1408-5 ↗
51. 10.1016/j.bios.2011.10.01310.1016/j.bios.2011.10.013 ↗
52. 10.1016/j.bios.2008.10.03210.1016/j.bios.2008.10.032 ↗
53. 10.1016/j.talanta.2018.02.03210.1016/j.talanta.2018.02.032 ↗
54. 10.1016/j.nantod.2021.10107610.1016/j.nantod.2021.101076 ↗
55. 10.1039/D4RA01422G10.1039/D4RA01422G ↗
56. 10.1529/biophysj.104.05480910.1529/biophysj.104.054809 ↗
57. 10.1152/ajpcell.00188.200610.1152/ajpcell.00188.2006 ↗
58. 10.1016/j.freeradbiomed.2008.10.03110.1016/j.freeradbiomed.2008.10.031 ↗
59. 10.1073/pnas.050171910210.1073/pnas.0501719102 ↗
60. 10.1039/C6NR02730J10.1039/C6NR02730J ↗
61. 10.1038/am.2013.8810.1038/am.2013.88 ↗
62. 10.1016/j.apsusc.2019.06.17710.1016/j.apsusc.2019.06.177 ↗
63. 10.1016/j.ijbiomac.2018.07.03010.1016/j.ijbiomac.2018.07.030 ↗
64. 10.3390/ma1817410610.3390/ma18174106 ↗
65. 10.1677/joe.0.170019710.1677/joe.0.1700197 ↗
66. 10.1039/b307162f10.1039/b307162f ↗
67. 10.1002/aesr.20220013810.1002/aesr.202200138 ↗
68. 10.1007/s10854-020-03636-910.1007/s10854-020-03636-9 ↗
69. 10.1021/acsnano.5c0176110.1021/acsnano.5c01761 ↗
70. 10.1113/jphysiol.1984.sp01538510.1113/jphysiol.1984.sp015385 ↗
71. 10.1371/journal.pone.017489910.1371/journal.pone.0174899 ↗
72. 10.1016/j.bbadis.2023.16689510.1016/j.bbadis.2023.166895 ↗
73. 10.3389/fphar.2021.71624810.3389/fphar.2021.716248 ↗
74. 10.3390/cells1209121510.3390/cells12091215 ↗
75. Dracorhodin Perchlorate Regulates the Expression of Inflammatory Cytokines through the TLR4 Pathway and Improves Skin Wound Healing in Diabetic Rats
76. 10.1046/j.0022-202x.2001.01600.x10.1046/j.0022-202x.2001.01600.x ↗
77. 10.1089/wound.2013.047310.1089/wound.2013.0473 ↗
78. 10.1046/j.1087-0024.2000.00014.x10.1046/j.1087-0024.2000.00014.x ↗
79. 10.1177/1559325823117990010.1177/15593258231179900 ↗
80. 10.1080/0192623060086774310.1080/01926230600867743 ↗
81. 10.1007/s00580-013-1745-110.1007/s00580-013-1745-1 ↗
82. 10.21315/mjms2020.27.1.510.21315/mjms2020.27.1.5 ↗
83. 10.1007/s10735-023-10137-610.1007/s10735-023-10137-6 ↗
84. 10.1038/s41598-022-18860-y10.1038/s41598-022-18860-y ↗
85. 10.3892/etm.2017.442010.3892/etm.2017.4420 ↗
86. 10.1016/j.heliyon.2023.e1414610.1016/j.heliyon.2023.e14146 ↗
87. 10.1016/j.sjbs.2013.02.00410.1016/j.sjbs.2013.02.004 ↗